SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, announces the granting of the first patent for its SkinBiotix® technology in Australia.
The patent granted covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease. This marks the Company’s first patent to progress to grant from within its portfolio of patents pending estate. The patent, numbered 2013246701 and entitled ‘Probiotic bacteria’, runs until 15 March 2033.
The patent is in active prosecution in other locations worldwide including Europe, USA and China.
Dr Catherine O’Neill, CEO of SkinBioTherapeutics plc, commented: “The Australian skincare market is a key global market. The progression and successful grant of the first national patent to emerge from the Company’s Skinbiotix® patent family underpins the commercial potential worldwide.
“This is a step forward in preparing for human trials, which are scheduled for 2018.”
SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
